As competition in the weight-loss drug market intensifies, Novo Nordisk has announced a comprehensive partnership with OpenAI to integrate artificial intelligence technology across its entire business chain, from drug research and development to manufacturing. This move aims to help the company regain ground in its competition with Eli Lilly.
According to reports, Novo Nordisk stated that the collaboration will cover multiple areas including drug discovery, manufacturing efficiency improvements, supply chain optimization, and corporate operations. Full integration is planned to be completed by the end of 2026. The manufacturer of Wegovy and Ozempic did not disclose specific financial terms of the agreement.
The announcement comes as Eli Lilly just received U.S. regulatory approval this month for its weight-loss pill Foundayo, further extending its lead over Novo Nordisk.
Following the news, Novo Nordisk's stock price rose by 1.23%, while Eli Lilly's stock declined by 1.06%. Analysts predict that the weight-loss drug market will generate annual revenues exceeding $100 billion over the next decade, with competition between the two companies expected to continue heating up.
The partnership represents a comprehensive AI deployment spanning from research to commercial operations. Under the agreement, Novo Nordisk will leverage OpenAI's technology to analyze complex datasets, screen potential drug candidate molecules, and enhance overall efficiency in manufacturing, supply chain, distribution, and corporate operations.
Novo Nordisk indicated that pilot projects will initially launch in three key areas: research and development, manufacturing, and commercial operations. The company plans to achieve full integration by the end of 2026. OpenAI will also assist Novo Nordisk in providing AI training to its global workforce, enhancing AI application capabilities and productivity across various departments.
OpenAI CEO Sam Altman stated in a declaration that AI is transforming various industries, and in the life sciences sector, it can help people live healthier and longer lives. The collaboration with Novo Nordisk will accelerate scientific discovery, optimize global operations, and redefine future patient care.
Novo Nordisk CEO Mike Doustdar clarified that the partnership's objective is not to replace existing scientists but to empower and accelerate their work. He emphasized that the collaboration will not lead to current employee reductions, though it will help control future hiring growth by improving per-person output.
This statement comes with specific context. Shortly after Doustdar became CEO last year, he announced a restructuring plan that eliminated 9,000 positions, a measure designed to address increasing competitive pressures in the weight-loss drug market.
The partnership with OpenAI is viewed externally as a strategic move following cost-cutting measures, now seeking to drive growth through technological means. Novo Nordisk also confirmed that the agreement includes strict data protection, governance mechanisms, and human oversight arrangements, building upon the company's existing AI collaborations.
The collaboration reflects a broader industry trend of pharmaceutical companies embracing AI. Drug manufacturers are increasingly applying AI to more tedious aspects of drug development, including identifying clinical trial participants, screening trial locations, and preparing regulatory submission documents.
However, industry executives generally acknowledge that AI has not yet fully delivered on expectations regarding the more challenging core task of discovering significant new molecules. This suggests that whether Novo Nordisk's partnership can truly create breakthrough advantages in drug research and development remains to be seen.
In terms of competitive landscape, Eli Lilly has continued to expand its lead this year. Following Novo Nordisk's introduction of oral Wegovy in January, Eli Lilly received approval for its weight-loss pill Foundayo this month, further consolidating its first-mover position in the oral weight-loss drug segment. Analysts project this market will surpass $100 billion in annual revenue over the next decade, indicating that the competition between these two companies is far from over.
Comments